UY30652A1 - N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida - Google Patents

N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida

Info

Publication number
UY30652A1
UY30652A1 UY30652A UY30652A UY30652A1 UY 30652 A1 UY30652 A1 UY 30652A1 UY 30652 A UY30652 A UY 30652A UY 30652 A UY30652 A UY 30652A UY 30652 A1 UY30652 A1 UY 30652A1
Authority
UY
Uruguay
Prior art keywords
methyl
quinolin
piperidin
hydroxyethyl
benzamide
Prior art date
Application number
UY30652A
Other languages
English (en)
Inventor
Jingbo Yan
Jie Liu
Megan Murphy King
Valerie Hoesch
Glen Ernest
Cathy Dantzman
Thomas Hudzik
Bui Khanh
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY30652A1 publication Critical patent/UY30652A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

N-(2-hidroxietil)-N-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida, sales farmacéuticamente aceptables de la misma y/o mezclas de la misma, al igual que composiciones famacéuticas de la misma, métodos de tratamiento que las emplea y procesos para preparar N-(2-hidroxietil)-N-metil-4-(quinolin-8-il(1-(tiazol-4ilmetil)piperidin-4-ilideno)metil)benzamida intermediarios de la misma.
UY30652A 2006-10-20 2007-10-19 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida UY30652A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86232706P 2006-10-20 2006-10-20

Publications (1)

Publication Number Publication Date
UY30652A1 true UY30652A1 (es) 2008-05-31

Family

ID=39314285

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30652A UY30652A1 (es) 2006-10-20 2007-10-19 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida

Country Status (33)

Country Link
US (2) US7659286B2 (es)
EP (1) EP2079735B1 (es)
JP (1) JP4668346B2 (es)
KR (1) KR20090065534A (es)
CN (1) CN101528739B (es)
AR (1) AR063345A1 (es)
AT (1) ATE543818T1 (es)
AU (2) AU2007313515B2 (es)
BR (1) BRPI0717631A2 (es)
CA (1) CA2667041C (es)
CL (1) CL2007003009A1 (es)
CO (1) CO6180450A2 (es)
CY (1) CY1112718T1 (es)
DK (1) DK2079735T3 (es)
ES (1) ES2379519T3 (es)
HK (1) HK1131556A1 (es)
HR (1) HRP20120344T1 (es)
IL (1) IL197876A0 (es)
MX (1) MX2009003974A (es)
MY (1) MY148880A (es)
NO (1) NO20091969L (es)
NZ (1) NZ577060A (es)
PE (2) PE20080892A1 (es)
PL (1) PL2079735T3 (es)
PT (1) PT2079735E (es)
RS (1) RS52260B (es)
RU (1) RU2454414C2 (es)
SA (1) SA07280549B1 (es)
SI (1) SI2079735T1 (es)
TW (1) TW200826939A (es)
UA (1) UA97648C2 (es)
UY (1) UY30652A1 (es)
WO (1) WO2008048171A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410347A (pt) * 2003-05-16 2006-05-30 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, métodos para as terapias da dor e de distúrbios gostrointestinais funcionais em animal de sangue quente, e, processo para preparação de um composto
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
JP2011520956A (ja) * 2008-05-20 2011-07-21 アストラゼネカ・アクチエボラーグ 不安大うつ病性障害を処置する方法
CN101906078B (zh) * 2009-06-08 2012-02-01 上海威智医药科技有限公司 噻唑衍生物的合成方法
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
WO2020061165A1 (en) 2018-09-21 2020-03-26 Garland Industries, Inc. Helical hardbanding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
WO1999033806A1 (en) * 1997-12-24 1999-07-08 Ortho-Mcneil Pharmaceutical, Inc. 4-[aryl(piperidin-4-yl)] aminobenzamides which bind to the delta-opioid receptor
US6492375B2 (en) 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
MXPA02006137A (es) 1999-12-20 2002-12-05 Neuromed Tech Inc Bloqueadores del canal de calcio parcialmente saturados.
JP2003525938A (ja) * 2000-03-03 2003-09-02 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ３−（ジアリールメチレン）−８−アザビシクロ［３．２．１］オクタン誘導体
SE0001208D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101768D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
SE0300105D0 (sv) * 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
SE0301444D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
BRPI0410347A (pt) 2003-05-16 2006-05-30 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, métodos para as terapias da dor e de distúrbios gostrointestinais funcionais em animal de sangue quente, e, processo para preparação de um composto
SE0301441D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0400025D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Also Published As

Publication number Publication date
US20080182875A1 (en) 2008-07-31
US7977355B2 (en) 2011-07-12
PE20140634A1 (es) 2014-06-19
AU2007313515A1 (en) 2008-04-24
MX2009003974A (es) 2009-04-27
RS52260B (en) 2012-10-31
HRP20120344T1 (hr) 2012-05-31
CA2667041A1 (en) 2008-04-24
US7659286B2 (en) 2010-02-09
PT2079735E (pt) 2012-05-07
JP2010506910A (ja) 2010-03-04
AU2010226996A1 (en) 2010-10-28
NZ577060A (en) 2011-01-28
CA2667041C (en) 2011-09-06
KR20090065534A (ko) 2009-06-22
AU2007313515B2 (en) 2010-11-25
ATE543818T1 (de) 2012-02-15
CL2007003009A1 (es) 2008-06-06
CN101528739A (zh) 2009-09-09
HK1131556A1 (es) 2010-01-29
JP4668346B2 (ja) 2011-04-13
IL197876A0 (en) 2009-12-24
SI2079735T1 (sl) 2012-05-31
TW200826939A (en) 2008-07-01
PE20080892A1 (es) 2008-09-11
PL2079735T3 (pl) 2012-07-31
CY1112718T1 (el) 2016-02-10
NO20091969L (no) 2009-05-20
CN101528739B (zh) 2011-11-30
RU2009111337A (ru) 2010-11-27
AR063345A1 (es) 2009-01-21
RU2454414C2 (ru) 2012-06-27
EP2079735B1 (en) 2012-02-01
CO6180450A2 (es) 2010-07-19
UA97648C2 (ru) 2012-03-12
ES2379519T3 (es) 2012-04-26
SA07280549B1 (ar) 2010-09-29
US20100160374A1 (en) 2010-06-24
WO2008048171A1 (en) 2008-04-24
BRPI0717631A2 (pt) 2013-10-29
EP2079735A4 (en) 2010-12-29
MY148880A (en) 2013-06-14
EP2079735A1 (en) 2009-07-22
DK2079735T3 (da) 2012-05-21

Similar Documents

Publication Publication Date Title
NO20084923L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
ECSP099476A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
UY30633A1 (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratada
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
NO20090628L (no) Pyridizinon derivativater
CR10766A (es) Inhibidores de metaloproteasa derivados de heterociclicos
NO20091395L (no) Nye tiofenderivater
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
DOP2011000360A (es) Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoico y acido monobenzoico de 2-(4((2-amino-4-metil-6-(pentilamino) primidin-5-ii)metil) fenil) acetato de 4-(dimetilamino) butilo
UY30779A1 (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
NO20082793L (no) Nye tiofenderivater
CR11106A (es) Inhibidores de cinasa p710 s6
EA201070619A1 (ru) Карбоксамидные, сульфонамидные и аминовые соединения от метаболических нарушений
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
CY1113594T1 (el) Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
CR10505A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
UY30410A1 (es) Aminopirazolopiridinas sustituidas y sus sales, composiciones farmaceuticas que las comprenden, metodos para prepararlas y sus usos
UY30048A1 (es) Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones
ATE500222T1 (de) Benzamid- und heteroarenderivate als cetp- inhibitoren
UY30652A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-ilideno)metil)benzamida
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
ECSP11011503A (es) Compuestos carboxamida y su uso como inhibidores de calpaína.
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170727